The Medicines Co. (MDCO)

30.52
0.69 2.30
NASDAQ : Health Technology
Prev Close 29.83
Open 29.97
Day Low/High 29.32 / 30.55
52 Wk Low/High 24.45 / 55.95
Volume 616.52K
Avg Volume 1.41M
Exchange NASDAQ
Shares Outstanding 72.90M
Market Cap 2.42B
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Medicines Company To Host Conference Call And Webcast Discussing Fourth-Quarter And Full-Year 2017 Financial Results

The Medicines Company To Host Conference Call And Webcast Discussing Fourth-Quarter And Full-Year 2017 Financial Results

The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Wednesday, February 21, 2018, at 8:30 a.

The Medicines Company To Participate In The Leerink Partners 7th Annual Global Healthcare Conference

The Medicines Company To Participate In The Leerink Partners 7th Annual Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Leerink Partners 7 th Annual Global Healthcare Conference on Wednesday, February 14, 2018, in New York City.

Atlassian, AeroVironment, Granite Construction: 'Mad Money' Lightning Round

Atlassian, AeroVironment, Granite Construction: 'Mad Money' Lightning Round

Jim Cramer focuses on Atlassian, AeroVironment, Granite Construction, Ford Motor, U.S. Concrete, Chesapeake Energy.

The Bottom? Not So Fast: Cramer's 'Mad Money' Recap (Tuesday 2/6/18)

The Bottom? Not So Fast: Cramer's 'Mad Money' Recap (Tuesday 2/6/18)

Jim Cramer says we've cleaned out the bear den, but fundamental concerns, such as bond yields and wage inflation, still loom.

Inclisiran's First Pivotal Trial Achieves Target Enrollment Ahead Of Schedule

Inclisiran's First Pivotal Trial Achieves Target Enrollment Ahead Of Schedule

The Medicines Company (NASDAQ: MDCO) today announced that the target of 1,500 patients randomized in the ORION-11 trial has been exceeded in 11 weeks - considerably beating its goal of 28 weeks.

The Medicines Company Announces Closing Of Divestiture Of Infectious Disease Business Unit To Melinta Therapeutics

The Medicines Company Announces Closing Of Divestiture Of Infectious Disease Business Unit To Melinta Therapeutics

The Medicines Company (NASDAQ:MDCO) today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc.

The Medicines Company To Present At The 36th Annual J. P. Morgan Healthcare Conference

The Medicines Company To Present At The 36th Annual J. P. Morgan Healthcare Conference

The Medicines Company (NASDAQ:MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.

The Medicines Company To Host Investor Day On January 23, 2018

The Medicines Company To Host Investor Day On January 23, 2018

The Medicines Company (NASDAQ:MDCO) today announced that it will host an Investor Day on Tuesday, January 23, 2018, from 10:00 a.

MDCO: Insiders vs. Shorts

The most recent short interest data was recently released for the 11/15/2017 settlement date, and Medicines Co is one of the most shorted stocks of the Russell 3000, based on 17.69 "days to cover" versus the median component at 4.67. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.

The Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

The Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

The Medicines Company (NASDAQ: MDCO) today announced that it has entered into a definitive agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc.

Interesting MDCO Put And Call Options For July 2018

Interesting MDCO Put And Call Options For July 2018

Investors in Medicines Co saw new options begin trading this week, for the July 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

The Medicines Company Names Dr. Fred Eshelman As Executive Chairman; Appoints Geno Germano To Its Board Of Directors

The Medicines Company Names Dr. Fred Eshelman As Executive Chairman; Appoints Geno Germano To Its Board Of Directors

The Medicines Company (NASDAQ:MDCO) today announced that its Board of Directors has appointed Fredric N.

The Medicines Company And Alnylam Pharmaceuticals Announce Initiation Of Phase III Clinical Trials Of Inclisiran

The Medicines Company And Alnylam Pharmaceuticals Announce Initiation Of Phase III Clinical Trials Of Inclisiran

The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc.

MacroGenics Soars on Collaboration with Incyte -- Biotech Movers

MacroGenics Soars on Collaboration with Incyte -- Biotech Movers

MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.

The Medicines Company Reports Third-Quarter 2017 Business And Financial Results

The Medicines Company Reports Third-Quarter 2017 Business And Financial Results

The Medicines Company (NASDAQ: MDCO) today reported its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical and operational activities.

The Medicines Company To Announce Third-Quarter 2017 Financial Results On October 25

The Medicines Company To Announce Third-Quarter 2017 Financial Results On October 25

The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, October 25, 2017, at 8:30 a.

The Medicines Company To Present New Data From TANGO II Study Of VABOMERE™ (meropenem And Vaborbactam) At IDWeek 2017

The Medicines Company To Present New Data From TANGO II Study Of VABOMERE™ (meropenem And Vaborbactam) At IDWeek 2017

The Medicines Company (NASDAQ:MDCO) today announced that new data from its TANGO II study of VABOMERE (meropenem and vaborbactam) will be presented this week at IDWeek 2017 in San Diego.

The Medicines Company To Present Data At IDWeek 2017 On Infectious Disease Portfolio Including Recently Approved Antibiotic VABOMERE™ (meropenem And Vaborbactam)

The Medicines Company To Present Data At IDWeek 2017 On Infectious Disease Portfolio Including Recently Approved Antibiotic VABOMERE™ (meropenem And Vaborbactam)

The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products will be featured in presentations at IDWeek 2017 to be held October 4-8, 2017 in San Diego.

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Jim Cramer says the market may be shaking off bad news and threats, but recent positivity is unusual. Don't speculate, be diversified and don't feel bad about taking profits.

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.

The Medicines Company Announces FDA Approval Of VABOMERE™ (meropenem And Vaborbactam)

The Medicines Company Announces FDA Approval Of VABOMERE™ (meropenem And Vaborbactam)

The Medicines Company (NASDAQ:MDCO) today announced that the U.S.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BBSI, CAFD, CNXC, GNRT, GSBD, MCRN, RLGY, SBLK Downgrades: BGFV, BWINA, DGICA, HLIT, JACK, MDCO, RRGB, SOHO, TARO, TNC, VSAT, VSI, XRAY Initiations: LNTH, VTVT, WING Read on to get TheStreet Quant Ratings' detailed report:

The Medicines Company Reports Second Quarter 2017 Business And Financial Results

The Medicines Company Reports Second Quarter 2017 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2017, and provided an update on its clinical and operational activities.

The Medicines Company To Announce Second-Quarter 2017 Financial Results On August 9

The Medicines Company To Announce Second-Quarter 2017 Financial Results On August 9

The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, August 9, 2017, at 8:30 a.

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Novavax, Medicines Co. and Biogen were among the biotech stock movers in premarket trading on July 25.

TheStreet Quant Rating: D (Sell)